235 related articles for article (PubMed ID: 33559357)
1. Real-world data of chronic myelomonocytic leukemia: A chinese single-center retrospective study.
Ma L; Jiang L; Yang W; Luo Y; Mei C; Zhou X; Xu G; Xu W; Ye L; Ren Y; Lu C; Lin P; Jin J; Tong H
Cancer Med; 2021 Mar; 10(5):1715-1725. PubMed ID: 33559357
[TBL] [Abstract][Full Text] [Related]
2. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
[TBL] [Abstract][Full Text] [Related]
3. [Clinical Characteristics and Survival Analysis of Patients with Chronic Myelomonocytic Leukemia].
Wang JY; Chen JF; Wang SF; Guo QH; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):476-482. PubMed ID: 37096522
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy Cirici B; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Jimenez Lorenzo MJ; Melchardt T; Egle A; Viniou AN; Patel BJ; Arnan M; Valent P; Roubakis C; Bernal Del Castillo T; Galanopoulos A; Calabuig Muñoz M; Bonadies N; Medina de Almeida A; Cermak J; Jerez A; Montoro MJ; Cortés A; Avendaño Pita A; Lopez Andrade B; Hellstroem-Lindberg E; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Larcher-Senn J; Greil R
Lancet Haematol; 2021 Feb; 8(2):e135-e148. PubMed ID: 33513373
[TBL] [Abstract][Full Text] [Related]
5. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
Zeidan AM; Hu X; Long JB; Wang R; Ma X; Podoltsev NA; Huntington SF; Gore SD; Davidoff AJ
Cancer; 2017 Oct; 123(19):3754-3762. PubMed ID: 28621841
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
Motohashi K; Fujisawa S; Doki N; Kobayashi T; Mori T; Usuki K; Tanaka M; Fujiwara S; Kako S; Aoyama Y; Onoda M; Yano S; Gotoh M; Kanamori H; Takahashi S; Okamoto S;
Leuk Lymphoma; 2018 Jun; 59(6):1332-1337. PubMed ID: 29032731
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Bazinet A; Darbaniyan F; Kadia TM; Venugopal S; Kanagal-Shamanna R; DiNardo CD; Borthakur G; Jabbour EJ; Daver NG; Pemmaraju N; Konopleva MY; Ravandi F; Sasaki K; Chien KS; Hammond D; Pierce SA; Kantarjian HM; Garcia-Manero G; Montalban-Bravo G
Cancer; 2023 Feb; 129(4):560-568. PubMed ID: 36458426
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.
Liu HD; Ahn KW; Hu ZH; Hamadani M; Nishihori T; Wirk B; Beitinjaneh A; Rizzieri D; Grunwald MR; Sabloff M; Olsson RF; Bajel A; Bredeson C; Daly A; Inamoto Y; Majhail N; Saad A; Gupta V; Gerds A; Malone A; Tallman M; Reshef R; Marks DI; Copelan E; Gergis U; Savoie ML; Ustun C; Litzow MR; Cahn JY; Kindwall-Keller T; Akpek G; Savani BN; Aljurf M; Rowe JM; Wiernik PH; Hsu JW; Cortes J; Kalaycio M; Maziarz R; Sobecks R; Popat U; Alyea E; Saber W
Biol Blood Marrow Transplant; 2017 May; 23(5):767-775. PubMed ID: 28115276
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
Short NJ; Jabbour E; Naqvi K; Patel A; Ning J; Sasaki K; Nogueras-Gonzalez GM; Bose P; Kornblau SM; Takahashi K; Andreeff M; Sanchez-Petitto G; Estrov Z; Dinardo CD; Montalban-Bravo G; Konopleva M; Alvarado Y; Bhalla KN; Fiskus W; Khouri M; Islam R; Kantarjian H; Garcia-Manero G
Am J Hematol; 2019 Jan; 94(1):74-79. PubMed ID: 30328139
[TBL] [Abstract][Full Text] [Related]
10. How I treat chronic myelomonocytic leukemia.
Solary E; Itzykson R
Blood; 2017 Jul; 130(2):126-136. PubMed ID: 28572287
[TBL] [Abstract][Full Text] [Related]
11. Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome.
Patnaik MM; Wassie EA; Lasho TL; Hanson CA; Ketterling R; Tefferi A
Am J Hematol; 2015 May; 90(5):411-6. PubMed ID: 25645147
[TBL] [Abstract][Full Text] [Related]
12. Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia.
Hunter AM; Zhang L; Padron E
Curr Treat Options Oncol; 2018 Oct; 19(12):67. PubMed ID: 30367269
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population.
Wedge E; Hansen JW; Dybedal I; Creignou M; Ejerblad E; Lorenz F; Werlenius O; Ungerstedt J; Holm MS; Nilsson L; Kittang AO; Antunovic P; Rohon P; Andersen MK; Papaemmanuil E; Bernard E; Jädersten M; Hellström-Lindberg E; Grønbæk K; Ljungman P; Friis LS
Transplant Cell Ther; 2021 Dec; 27(12):991.e1-991.e9. PubMed ID: 34500124
[TBL] [Abstract][Full Text] [Related]
14. Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.
Tremblay D; Rippel N; Feld J; El Jamal SM; Mascarenhas J
Oncologist; 2021 May; 26(5):406-421. PubMed ID: 33792103
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of intermediate or high-risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience.
Li C; Deng C; Wu P; Liu K; Huang X; Li M; Chen X; Geng S; Lai P; Weng J; Du X
Clin Transl Sci; 2024 Jan; 17(1):e13711. PubMed ID: 38129985
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia.
Gagelmann N; Bogdanov R; Stölzel F; Rautenberg C; Panagiota V; Becker H; Radujkovic A; Luft T; Christopeit M; Finke J; Platzbecker U; Ditschkowski M; Schroeder T; Koldehoff M; Heuser M; Kobbe G; Beelen DW; Germing U; Kröger N
Transplant Cell Ther; 2021 Jan; 27(1):95.e1-95.e4. PubMed ID: 33039516
[TBL] [Abstract][Full Text] [Related]
17. Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study.
Itonaga H; Iwanaga M; Aoki K; Aoki J; Ishiyama K; Ishikawa T; Sakura T; Fukuda T; Najima Y; Yujiri T; Mori T; Kurokawa M; Nawa Y; Uchida N; Morishita Y; Hashimoto H; Eto T; Hirokawa M; Morishima Y; Nagamura-Inoue T; Atsuta Y; Miyazaki Y
Leuk Res; 2016 Feb; 41():48-55. PubMed ID: 26754557
[TBL] [Abstract][Full Text] [Related]
18. Current management of patients with chronic myelomonocytic leukemia.
Mora E; Sanz GF
Curr Opin Oncol; 2018 Nov; 30(6):409-417. PubMed ID: 30169461
[TBL] [Abstract][Full Text] [Related]
19. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis.
Robin M; de Wreede LC; Padron E; Bakunina K; Fenaux P; Koster L; Nazha A; Beelen DW; Rampal RK; Sockel K; Komrokji RS; Gagelmann N; Eikema DJ; Radujkovic A; Finke J; Potter V; Killick SB; Legrand F; Solary E; Broom A; Garcia-Manero G; Rizzoli V; Hayden P; Patnaik MM; Onida F; Yakoub-Agha I; Itzykson R
Blood; 2022 Sep; 140(12):1408-1418. PubMed ID: 35667047
[TBL] [Abstract][Full Text] [Related]
20. Analyses on clinical characteristic and prognoses of 41 patients with chronic myelomonocytic leukemia in China.
Chen B; Ma Y; Xu X; Wang X; Qin W; Ji M; Lin G
Leuk Res; 2010 Apr; 34(4):458-62. PubMed ID: 19631982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
